|
|
Nanotechnology in Healthcare: Market outlook for applications, tools and materials, and 40 company profiles
|
Zahlen und Fakten zur Studie: | 221 Pages | |||||||||
| Inhalt der Studie: |
The advent of healthcare nanotechnology has had a vast impact in the fields of drug delivery and diagnostics. The role of nanotechnology in healthcare is very important in terms of eradicating disease.....
The advent of healthcare nanotechnology has had a vast impact in the fields of drug delivery and diagnostics. The role of nanotechnology in healthcare is very important in terms of eradicating diseases, especially in terms of treating cancer. Advanced technological developments in coatings and implants using nanotechnology is expected to increase the scope of the market in various applications. This report covers different regional application markets, while evaluating them over the next five years. It provides information about the largest regional markets and factors influencing them, while defining the opportunities they present. Key features of this report • •Provides an analysis of market data (revenues) of healthcare nanotechnology applications in North America, Europe, Asia and Rest of World that includes Middle East, Africa, Russia, Latin America and Australia. • Studies key market drivers and restraints for the main market and evaluation of respective sub segments with respect to market dynamics. • Discusses drug delivery and formulations, biocompatible implants, regenerative medicine and wound care and diagnostics under the applications market along with related sub segments. Scope of this report • Understanding the existing and emerging applications of healthcare nanotechnology and their relative and forecast market sizes • Understanding the product/technological developments on which the companies are focusing for their growth. • Understanding the different nanotechnology based tools and their importance in the development of new products and applications Key Market Issues • Nanotechnology initiatives by developing countries are helping in the development of new products and applications. • The delay in commercialization due to strict regulations and manufacturing difficulties is inhibiting product reach. • Stability of nanoparticles inside the biological tissues is an important issue to be considered to reduce contamination by drugs. • The development of biodegradable nanostructures will be a growth driver in future since they eliminate the issue of excretion. Key findings from this report • The healthcare nanotechnology market growth is largest in North America, at $4.75bn in 2009, followed by Europe at $3.65. • The nanotechnology drug delivery market is expected to grow at a CAGR of 21.7% for the period 2009-14, to reach almost $16bn by 2014. • Biocompatible implants and coatings and diagnostics comprise some of the major applications which are estimated to experience high growth between 2009 and 2014, 42% and 21.8% respectively. Key questions answered • What are the important healthcare nanotechnology markets and their growth over the period 2009-14? • What are the major applications that have emerged in different areas such as drug formulations and delivery, biocompatible implants and coatings, regenerative medicines and wound care and diagnostics? • In which areas are the companies focusing while forming strategic alliances with other industry players? Report Highlights Companies mentioned in the report: Abraxis BioSciences, AstraZeneca, Capsulution Nanoscience AG, Do-Coop, Elan Corporation, J.R. Nanotech, Liquidia Technologies, Merck KGaA, Novartis, Pioneer Surgical, Smith & Nephew,Star Pharma and Wyeth Pharmaceutical [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Nanotechnology in Healthcare Executive summary 16 Market overview 16 Healthcare nanotechnology market dynamics 16 Nanomaterials & nanotools for the healthcare market 17 Healthcare nanotechnology application market 18 Company profiles 19 Chapter 1 Market overview 22 Summary 22 Introduction 23 Market definition 23 Healthcare nanotechnology business processes 24 Healthcare nanotechnology applications 24 Healthcare nanotechnology application prospects 25 Opportunity matrix 26 Challenge matrix 28 Patent analysis 29 Chapter 2 Healthcare nanotechnology market dynamics 34 Summary 34 Introduction 35 Regional markets 36 North America 37 Europe 38 Asia 38 RoW 39 Competitive landscape 39 R&D activities by applications 41 New product launches 42 Collaborations & agreements 43 Market drivers 56 Nanotechnology research initiatives in developing nations 56 Innovations are increasing 56 Reduced toxicity 56 Market inhibitors 57 Delay in commercialization 57 Stability and other issues 57 Need for particle evaluation 57 Chapter 3 Nanomaterials & nanotools for the healthcare market 60 Summary 60 Introduction 61 Nanomaterials 61 Nanocapsules 61 Drivers 61 Inhibitors 62 Opportunities 62 Nanoporous materials 63 Drivers 63 Opportunities 63 Quantum dots 63 Drivers 64 Inhibitors 64 Opportunities 64 Nanotubes 65 Drivers 65 Nanowires 65 Drivers 66 Inhibitors 66 Opportunities 66 Dendrimers 67 Drivers 67 Opportunities 68 Monoclonal antibodies 68 Drivers 68 Inhibitors 69 Opportunities 69 Nanocomposites 69 Fullerenes 70 Nanofilms 70 Drivers 71 Inhibitors 71 Opportunities 71 Nanotools 72 Nanoarrays 72 Drivers 72 Inhibitors 73 Opportunities 73 Nanobiochip 74 Drivers 74 Opportunities 75 Nanolithography arrays 75 Drivers 75 Inhibitors 76 Opportunities 76 Computer-assisted drug discovery 77 Nanomass spectrometry 77 Drivers 77 Inhibitors 78 Opportunities 78 Congruent Force Intermolecular Test (nanotype) C-FIT 78 Chapter 4 Healthcare nanotechnology application market 82 Summary 82 Introduction 83 Drug formulation and delivery 83 Formulation 84 Drivers 85 Inhibitors 86 Opportunities 86 Fluorescently encoded microparticles 86 Nanoparticulate formulation/systems 88 Fluoropolymers as material platforms for drug therapy 88 DNA nanoparticle technology to produce DNA drugs 89 Drug profiling using smart materials 90 Supercritical fluids and water based nanomaterials 91 Dendrimer nanotechnology products 92 Potential healthcare nanotechnology drug formulation application 93 Drug delivery 93 Drivers 94 Inhibitors 95 Opportunities 95 Nanoencapsulation using nano-device platform 96 Smart materials for encapsulation 97 Antimicrobial nanoencapsulation 98 Nanoscale cochlear drug delivery 99 Drug delivery using nanoparticles 99 Nanocrystals for drug delivery 102 Drug delivery coatings 103 Nanopores 103 Nanocomposites 104 Nanotransponders 105 Potential applications of healthcare nanotechnology drug delivery 105 Biocompatible implants and coatings 106 Drivers 108 Nanofibers fight immune response 108 Improvement in biocompatibility 108 Optimized coatings 108 Improvement in dental implants 108 Inhibitors 108 Improvement of implant depends upon coatings 108 Possibility of mass poisoning 109 Opportunities 109 Improved brain implants 109 Improvement in process for better coatings 109 Helpful in orthopedic devices 109 Surface modification 109 Device coating 110 Drivers 112 Inhibitors 112 Opportunities 112 Sol-gel coatings 113 Biocompatible nanocoatings 113 Nanoscale plasma coating 113 Light-activated antimicrobials 113 Silver nanoparticles 114 Hydrophobic coatings 114 Multifunctional coatings 114 Anti-fouling nanocoatings 114 Passive hydroxyapatite coating 115 Other protective coatings 115 Implants 116 Drivers 116 Opportunities 117 Potential biocompatible implants applications 117 Life support devices using novel biocompatible polymers 117 Stimulation electrodes using nanotechnology 117 Noninvasive killing of cancer cells using localized heat 118 Artificial vascular grafts 118 Bone graft substitutes 118 Regenerative medicine and wound care 118 Regenerative medicine/tissue engineering 119 Drivers 120 Inhibitors 121 Opportunities 121 Potential applications of regenerative medicines 123 Wound care 124 Drivers 124 Opportunities 125 Nanosilver gels 125 Nanogold gels 125 Diagnostics 126 Drivers 127 Improved bioassays 127 Earlier diagnosis and effective monitoring 127 Opportunities 127 Treatment of ovarian cancer 127 Development of immunoassays 128 Quantum dots applications 128 Nanoemulsions in multimodal molecular imaging and targeted therapeutics 128 Nanoparticles for biochemical applications 129 Magnetic nanoparticles for medical diagnostic imaging 129 Encapsulation of radioactive nanoparticle 129 Genome sequencing 129 Nanobiosensors 130 Nanoarray biochips 130 Silicon-based chips/sensors for pH and pressure 130 Micro- and nano-replication for point-of-use analytical applications 131 Nanocells 131 Redox enzymes 131 Other potential diagnostics applications 132 Smart card diagnostics 132 Novel microfluidic technologies 132 Chapter 5 Company profiles 134 Summary 134 Abraxis BioScience, Inc. 135 Company overview 135 Products and services 135 Company strategy 136 Access Pharmaceuticals, Inc. 137 Company overview 137 Products and services 137 Company strategy 138 AstraZeneca 138 Company overview 138 Products and services 139 Company strategy 139 AMAG Pharmaceuticals, Inc. 139 Company overview 139 Products and services 140 Company strategy 140 Aphios Corp. 140 Company overview 141 Products and services 141 Company strategy 142 Asklepios Biopharmaceutical Inc. 142 Company overview 143 Products and services 143 Company strategy 143 Capsulution Nanoscience AG 144 Company overview 144 Products and services 144 Company strategy 144 ConvaTec 145 Company overview 145 Products and services 145 Company strategy 146 Debiotech 146 Company overview 146 Products and services 146 Company strategy 147 Do-Coop Technologies Ltd. 147 Company overview 147 Products and services 147 Company strategy 148 Elan Corp. 148 Company overview 148 Products and services 148 Company strategy 149 Ferro Corp. 149 Company overview 149 Products and services 150 Company strategy 150 Flamel Technologies 150 Company overview 151 Products and services 151 Company strategy 151 GE Global Research 152 Company overview 152 Company strategy 152 GfE Medizintechnik GmbH 153 Company overview 153 Products and services 153 Company strategy 154 HemCon Medical Technologies, Inc. 154 Company overview 154 Company strategy 155 iCeutica Inc 155 Company overview 155 Products and services 156 Company strategy 156 Liquidia Technologies 157 Company overview 157 Company strategy 157 Luna Innovations Inc. 158 Company overview 158 Products and services 158 Company strategy 159 MagForce Nanotechnologies AG 159 Company overview 160 Products and services 160 Company strategy 161 Merck KGaA 161 Company overview 161 Products and services 162 Company strategy 162 MIV Therapeutics Inc 162 Company overview 163 Products and services 163 Company strategy 163 Nanomix 163 Company overview 164 Products and services 164 Company strategy 164 Nano Interface Technology, Inc 165 Company overview 165 Products and services 165 Company strategy 165 NanoCarrier Co., Ltd. 165 Company overview 166 Products and services 166 Company strategy 166 NanoDel Technologies 167 Company overview 167 Products and services 167 Company strategy 167 NanoHorizons Inc. 168 Company overview 168 Products and services 168 Company strategy 168 Nanoprobes, Inc. 169 Company overview 169 Products and services 169 Company strategy 169 Nanospectra Biosciences Inc. 170 Company overview 170 Products and services 170 Company strategy 170 Nanosphere, Inc. 171 Company overview 171 Products and services 171 Company strategy 172 Novartis AG 172 Company overview 173 Products and services 173 Company strategy 173 Pfizer 173 Company overview 173 Company strategy 174 PharmaSol GmbH 174 Company overview 174 Products and services 174 Company strategy 175 Pioneer Surgical Technology 175 Company overview 175 Products and services 175 Company strategy 176 pSivida 176 Company overview 176 Products and services 176 Company strategy 176 F. Hoffmann–La Roche Ltd. 177 Company overview 177 Products and services 177 Company strategy 177 Siemens Medical Solutions 178 Company overview 178 Products and services 179 Company strategy 179 Smith & Nephew 179 Company overview 179 Products and services 180 Company strategy 180 Starpharma Holdings Ltd. 181 Company overview 181 Products and services 181 Company strategy 182 T2 Biosystems Inc. 183 Company overview 183 Company strategy 183 Appendix 184 Patents 184 Glossary 218 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Table 2.1: Global healthcare nanotech market, by geography ($m), 2007-14 37 Table 2.2: Mergers & acquisitions in healthcare nanotech market, 2007–09 44 Table 2.3: New product launches in healthcare nanotech market, 2007–09 45 Table 2.4: New product launches in healthcare nanotech market, 2007–09 (ctd) 46 Table 2.5: R&D in healthcare nanotech market, 2007–09 47 Table 2.6: R&D in healthcare nanotech market, 2007–09 (ctd 1) 48 Table 2.7: R&D in healthcare nanotech market, 2007–09 (ctd 2) 49 Table 2.8: R&D in healthcare nanotech market, 2007–09 (ctd 3) 50 Table 2.9: R&D in healthcare nanotech market, 2007–09 (ctd 4) 51 Table 2.10: R&D in healthcare nanotech market, 2007–09 (ctd 5) 52 Table 2.11: R&D in healthcare nanotech market, 2007–09 (ctd 6) 53 Table 2.12: Collaborations & agreements in healthcare nanotech market, 2007–09 54 Table 2.13: Collaborations & agreements in healthcare nanotech market, 2007–09 (ctd) 55 Table 4.14: Global healthcare nanotech drug formulation and delivery market, by product ($m), 2007–14 83 Table 4.15: Global healthcare nanotech drug formulation and delivery market, by geography ($m), 2007–14 84 Table 4.16: Global healthcare nanotechnology drug formulation market, by product ($m), 2007–14 85 Table 4.17: Global healthcare nanotech fluorescently encoded microparticles market, by geography ($m), 2007–14 87 Table 4.18: Global healthcare nanotech nanoparticulate formulation/systems market, by geography ($m), 2007–14 88 Table 4.19: Global healthcare nanotech fluoropolymers material platforms for drug therapy market, by geography ($m), 2007–14 89 Table 4.20: Global healthcare DNA nanoparticle technology to produce DNA drugs market, by geography ($m), 2007-14 90 Table 4.21: Global healthcare nanotech drug profiling using smart materials market, by geography ($m), 2007-14 91 Table 4.22: Global healthcare nanotech supercritical fluids and water based nanomaterials market, by geography ($m), 2007-14 91 Table 4.23: Global dendrimer nanotech products market by geography ($m), 2007-14 92 Table 4.24: Global healthcare nanotech drug delivery market by product ($m), 2007-14 94 Table 4.25: Global healthcare nanoencapsulation using nano-device platform market, by product ($m), 2007-14 96 Table 4.26: Global healthcare nanoencapsulation using nano-device platform market, by geography ($m), 2007-14 97 Table 4.27: Global market for smart materials encapsulating pharmaceuticals, by geography ($m), 2007-14 98 Table 4.28: Global healthcare nanotech antimicrobial nanoencapsulation, by geography ($m), 2007-14 98 Table 4.29: Global healthcare nanotech nanoscale cochlear drug delivery, by geography ($m), 2007-14 99 Table 4.30: Global healthcare nanotech drug delivery using nanoparticles market, by product ($m), 2007-14 100 Table 4.31: Global healthcare nanotech drug delivery using nanoparticles market, by geography ($m), 2007-14 100 Table 4.32: Global drug delivery using nanocrystals market, by geography ($m), 2007-14 102 Table 4.33: Global healthcare nanotech drug delivery coatings market, by geography ($m), 2007- 14 103 Table 4.34: Global healthcare nanopores market, by geography ($m), 2007-14 104 Table 4.35: Global healthcare nanocomposites market, by geography ($m), 2007-14 104 Table 4.36: Global healthcare nanotech nanotransponder market, by geography ($m), 2007-14 105 Table 4.37: Global healthcare nanotech biocompatible implants and coatings market, by products ($m), 2007-14 107 Table 4.38: Global healthcare nanotech biocompatible implants and coatings market, by geography ($m), 2007-14 107 Table 4.39: Global healthcare nanotech surface modification market, by geography ($m), 2007-14 110 Table 4.40: Global healthcare nanotech device coating market, by products ($m), 2007-14 111 Table 4.41: Global healthcare nanotech device coating market, by geography ($m), 2007-14 111 Table 4.42: Global healthcare nanotech implants market, by geography ($m), 2007-14 116 Table 4.43: Global healthcare nanotech regenerative medicine and wound care market, by products ($m), 2007-14 119 Table 4.44: Global healthcare nanotech regenerative medicine market, by product ($m), 2007-14 120 Table 4.45: Global healthcare nanotech wound care market, by products ($m), 2007-14 124 Table 4.46: Global healthcare nanotech diagnostics market, by products ($m), 2007-14 126 Table 4.47: Global healthcare nanotech diagnostics market, by geography ($m), 2007-14 127 Table 0.48: US patents 184 Table 0.49: US patents (ctd 1) 185 Table 0.50: US patents (ctd 2) 186 Table 0.51: US patents (ctd 3) 187 Table 0.52: US patents (ctd 4) 188 Table 0.53: US patents (ctd 5) 189 Table 0.54: US patents (ctd 6) 190 Table 0.55: US patents (ctd 7) 191 Table 0.56: US patents (ctd 8) 192 Table 0.57: US patents (ctd 9) 193 Table 0.58: US patents (ctd 10) 194 Table 0.59: US patents (ctd 11) 195 Table 0.60: US patents (ctd 12) 196 Table 0.61: US patents (ctd 13) 197 Table 0.62: US patents (ctd 14) 198 Table 0.63: US patents (ctd 15) 199 Table 0.64: US patents (ctd 16) 200 Table 0.65: US patents (ctd 17) 201 Table 0.66: US patents (ctd 18) 202 Table 0.67: US patents (ctd 19) 203 Table 0.68: Europe patents 204 Table 0.69: Europe patents (ctd 1) 205 Table 0.70: Europe patents (ctd 2) 206 Table 0.71: Europe patents (ctd 3) 207 Table 0.72: Europe patents (ctd 4) 208 Table 0.73: Europe patents (ctd 5) 209 Table 0.74: Europe patents (ctd 6) 210 Table 0.75: Europe patents (ctd 7) 211 Table 0.76: Europe patents (ctd 8) 212 Table 0.77: Europe patents (ctd 9) 213 Table 0.78: Europe patents (ctd 10) 214 Table 0.79: Europe patents (ctd 11) 215 Table 0.80: Japan patents 216 Table 0.81: Japan patents (ctd 1) 217 List of Figures Figure 1.1: Global healthcare nanotechnology market 23 Figure 1.2: Geographical patent share, 2003-08 30 Figure 1.3: Number of patents by region, 2003-09 30 Figure 1.4: Comparison of patent trends, 2004 vs 2009 31 Figure 2.5: Developmental strategies by major players, January 2007–November 2009 40 Figure 2.6: R&D activities by applications, Jan 2007–Nov 2009 41 Figure 2.7: New product launches, Jan 2007–Nov 2009 42 Figure 2.8: Collaborations & agreements by applications, Jan 2007–Nov2009 43 Figure 2.9: Relative importance of features of healthcare nanotechnology 58 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||


